News | Brachytherapy Systems | October 31, 2018

Eighty-two percent of men in single-institution study reported no complications at four months post-procedure

Prostate Brachytherapy Shows Low Incidence of Short-Term Complications

October 31, 2018 — A new analysis of nearly 600 men receiving brachytherapy for prostate cancer shows overall procedure-related complications within four months of treatment is less than 20 percent. All patients were treated at Fox Chase Cancer Center in Philadelphia.

Brachytherapy is a form of internal radiation therapy in which doctors implant permanent or temporary radioactive sources into the prostate. It confines the radiation to the tumor and reduces radiation exposure to the surrounding healthy tissues. It can be administered either as permanent low dose-rate (LDR) implant, or as temporary high dose-rate (HDR) implant. In this study, 97 men received HDR and 485 received LDR.

Of the 582 men studied, 477, or 82 percent reported no complications. The most common complication within four months was lower urinary tract symptoms, which affected 8.4 percent of the patients.

Douglas Lee, DO, a radiation oncology resident at Fox Chase, led the study and presented it at an oral session at the 60th Annual Meeting of the American Society for Radiation Oncology (ASTRO), Oct. 21-24 in San Antonio, Texas.

“There have been several studies of long-term complications associated with brachytherapy, but this is one of the largest analyses of the near-term procedural complications,” Lee said. “Our findings add to the data showing that brachytherapy is safe for men treated at a single institution with expertise in this treatment.”

In the United States, prostate cancer is the most commonly diagnosed cancer in men. Nearly 200,000 cases are diagnosed in each year. It is frequently treatable, especially when diagnosed at earlier stages.

Read more about late-breaking clinical trials presented at ASTRO 2018.

For more information: www.astro.org

Related Content

News | Radiation Therapy

January 13, 2022 — A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides guidance ...

Time January 13, 2022
arrow
News | Radiology Imaging

January 12, 2022 — Machine-learning methods are being actively developed for computed imaging systems like magnetic ...

Time January 12, 2022
arrow
News | PET Imaging

January 11, 2022 — Clario, a technology company that delivers the leading endpoint technology solutions for clinical ...

Time January 11, 2022
arrow
News | Radiation Therapy

January 10, 2022 — Nanobiotix, a late-stage clinical biotechnology company pioneering physics-based approaches to expand ...

Time January 10, 2022
arrow
News | Radiation Oncology

January 7, 2022 — A Case Western Reserve University-led team of scientists has used Artificial Intelligence (AI) to ...

Time January 07, 2022
arrow
News | Proton Therapy

January 3, 2022 — IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and ...

Time January 03, 2022
arrow
News | Radiation Oncology

December 30, 2021 — IBA (Ion Beam Applications S.A), a world leader in particle accelerator technology, announced the ...

Time December 30, 2021
arrow
News | Radiation Therapy

December 29, 2021 — Researchers at the University of Surrey have identified key design rules for making curved X-ray ...

Time December 29, 2021
arrow
News | Magnetic Resonance Imaging (MRI)

December 23, 2021 — Advancements in medical science have allowed the treatment of psychiatric disorders like major ...

Time December 23, 2021
arrow
News | Coronavirus (COVID-19)

December 23, 2021 — An interdisciplinary research team from the University of Göttingen and Hannover Medical School (MHH ...

Time December 23, 2021
arrow
Subscribe Now